Sugi Predict
/ Targets
/ TNKS2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to TNKS2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) |
PHASE1/PHASE2 | COMPLETED |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib |
PHASE2 | COMPLETED |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations |
PHASE1/PHASE2 | COMPLETED |
| Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Telaglenastat + Talazoparib In Prostate Cancer |
PHASE2 | UNKNOWN |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer |
PHASE1 | COMPLETED |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer |
PHASE1 | UNKNOWN |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts |
PHASE1 | ACTIVE_NOT_RECRUITING |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
PHASE1 | WITHDRAWN |
| PET Imaging of PARP Activity in Cancer |
EARLY_PHASE1 | UNKNOWN |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
nan | NO_LONGER_AVAILABLE |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility |
nan | RECRUITING |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| Telomeres Length in Israeli Fibrotic ILD Patients |
nan | ENROLLING_BY_INVITATION |
Related proteins — ESM-2 sequence neighbours (a TNKS2 binder may also engage these)